YORK, April 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences
Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical
company focused on novel cancer immunotherapies for a broad
range of cancer indications, today announced the appointment
of Gene Mack as Chief Financial Officer and Treasurer.
We are delighted to welcome Gene to our executive team.
He has a proven track record of leveraging his deep expertise
in corporate finance and strategy to help companies develop
important therapies for patients and deliver significant value
for shareholders, said Angelos Stergiou, M.D., ScD h.c.,
President and Chief Executive Officer of SELLAS. That
experience, coupled with his leadership ability, will be of
great value to SELLAS as we continue to advance our pipeline
of novel cancer immunotherapies and expand our management team.
Mr. Mack joins SELLAS having served as a consulting chief financial
officer for a number of private and publicly traded biotechnology
and pharmaceutical companies, developing strategy and leading
management of all company finance, accounting, and treasury
functions, most recently with Nicox, SA. Prior to consulting,
Mr. Mack held finance and business development positions at
Ascendia Pharmaceuticals and Edge Therapeutics. Over the past
5 years, Mr. Mack has raised over $300 million in equity and
debt financing while also advising on numerous successful M&A
and product licensing transactions. Mr. Mack also spent over
13 years as a senior publishing analyst in life sciences equity
research at Brean Capital, Lazard, and HSBC Capital Markets.
Mr. Mack began his career conducting clinical research at Columbia
University College of Physicians and Surgeons. Mr. Mack holds
a B.S. in Biochemistry and an M.B.A. in Finance, both from Fordham
With a diverse, late-stage pipeline of immunotherapies,
SELLAS has the potential to bring innovative new treatments
to patients with life-threatening diseases, said Mr. Mack.
I am thrilled to join SELLAS experienced leadership
team and look forward to contributing to the companys
growth at this exciting time. Interim Chief Financial
Officer Aleksey Krylov will remain with SELLAS until July 15th
in order to facilitate the transition. I would like to
thank Aleksey for his service as Interim Chief Financial Officer.
He has achieved multiple milestones for SELLAS, including the
completion of our reverse merger and the closing of our recent
strategic financing, said Dr. Stergiou.
About SELLAS Life Sciences Group: SELLAS is a clinical-stage
biopharmaceutical company focused on novel cancer immunotherapeutics
for a broad range of cancer indications. SELLAS lead product
candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan
Kettering Cancer Center and targets the Wilms Tumor 1 (WT1)
protein, which is present in an array of tumor types. GPS has
potential as a monotherapy or in combination to address a broad
spectrum of hematologic malignancies
and solid tumor indications. SELLAS has Phase 3 clinical trials
planned (pending funding availability) for GPS in two indications,
acute myeloid leukemia (AML) and malignant pleural mesothelioma
(MPM) and is also developing GPS as a potential treatment for
multiple myeloma and ovarian cancer. SELLAS plans to study GPS
in up to four additional indications. SELLAS has received Orphan
Drug designations from the U.S. Food & Drug Administration
(FDA), as well as the European Medicines Agency, for GPS in
AML and MPM; GPS also received Fast Track designation for AML
and MPM from the FDA.